A Study to Optimize Subretinal Surgical Delivery & to Evaluate Safety &

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06161584` - A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Active, not recruiting	`NCT05536297` - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy	Phase 3
Completed	`NCT02515942` - CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)	Phase 2
Completed	`NCT02503332` - Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy	Phase 2
Recruiting	`NCT04339764` - Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT03295877` - Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)	Phase 1
Completed	`NCT01445548` - Sirolimus for Advanced Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT00973011` - A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy	Phase 1
Terminated	`NCT02247479` - A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration	Phase 3
Active, not recruiting	`NCT06006585` - A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy	Phase 1
Recruiting	`NCT05961332` - COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy	N/A
Terminated	`NCT02247531` - A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration	Phase 3
Completed	`NCT02332343` - Sparing of the Fovea in Geographic Atrophy Progression	N/A
Completed	`NCT01002950` - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy	Phase 2
Completed	`NCT03777332` - Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy	Phase 1
Active, not recruiting	`NCT04676854` - Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD	N/A
Recruiting	`NCT02372916` - Geographic Atrophy and Intravitreal Ranibizumab Injections	N/A
Active, not recruiting	`NCT05380492` - Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration	Phase 1/Phase 2
Terminated	`NCT04607148` - A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration	Phase 2
Terminated	`NCT02087085` - A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration	Phase 2

NCT number	NCT05626114
Study type	Interventional
Source	Genentech, Inc.
Contact	Reference Study ID Number: GR44251 https://forpatients.roche.com
Phone	888-662-6728 (U.S. Only)
Email	global-roche-genentech-trials@gene.com
Status	Recruiting
Phase	Phase 2
Start date	March 24, 2023
Completion date	April 11, 2029

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms